source
- Eli Lilly to acquire cancer cell therapy startup Kelonia Therapeutics for $3.2 billionEli Lilly announced it will buy privately held Kelonia Therapeutics, a biotech focused on cell therapies for cancer and autoimmune diseases, in a deal valued at $3.2 billion. Kelonia has operated…
- FDA to fast-track review of three psychedelic therapies for depression and PTSDThe FDA announced it will accelerate the review of psychedelic drugs from three companies as part of a broader initiative to increase access to mental-health treatments. Compass Pathways will rece…